The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Royal Marsden NHS Foundation Trust · Institute of Cancer Research · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
557
total citations
- FWCI
- 27.70
- Percentile
- 100%
- References
- 34
Citations per year
Authors
22- SSShahneen Sandhu
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Peter MacCallum Cancer Centre
- WRWilliam R. Schelman
University of Wisconsin Carbone Cancer Center
- GWGeorge Wilding
University of Wisconsin Carbone Cancer Center
- VMVíctor Moreno
Institute of Cancer Research, Royal Marsden NHS Foundation Trust
- RDRichard D. Baird
Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Topics & keywords
Topics
Keywords
- Poly ADP ribose polymerase
- Polymerase
- Cancer research
- Mutation
- Medicine
- Cancer
- Oncology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.